Clinical Observation of Whole Brain Radiotherapy Concomitant with Targeted Therapy for Brain Metastasis in Non-small Cell Lung Cancer Patients with Chemotherapy Failure

被引:30
作者
Cai, Yong [1 ]
Wang, Ji-Ying [2 ]
Liu, Hui [1 ]
机构
[1] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Radiat Oncol, Shanghai 200092, Peoples R China
[2] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Oncol, Shanghai 200092, Peoples R China
关键词
Non-small cell lung cancer; brain metastasis; whole brain radiotherapy; targeted therapy; clinical effect; PHASE-II; COMBINATION; RADIATION; INHIBITOR; GEFITINIB; ERLOTINIB; IRESSA; ZD1839; TRIAL;
D O I
10.7314/APJCP.2013.14.10.5699
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To investigate the clinical effects of whole brain radiotherapy concomitant with targeted therapy for brain metastasis in non-small cell lung cancer (NSCLC) patients with chemotherapy failure. Materials and Methods: Of the 157 NSCLC patients with chemotherapy failure followed by brain metastasis admitted in our hospital from January 2009 to August 2012, the combination group (65 cases) were treated with EGFR-TKI combined with whole brain radiotherapy while the radiotherapy group (92 cases) were given whole brain radiotherapy only. Short-term effects were evaluated based on the increased MRI in brain 1 month after whole brain radiotherapy. Intracranial hypertension responses, hematological toxicity reactions and clinical effects of both groups were observed. Results: There were more adverse reactions in the combination group than in radiotherapy group, but no significant differences were observed between the two groups in response rate (RR) and disease control rate (DCR) (P>0.05). Medium progression free survival (PFS), medium overall survival (OS) and 1-year survival rate in combination group were 6.0 months, 10.6 months and 42.3%, while in the radiotherapy group they were 3.4 months, 7.7 months and 28.0%, respectively, which indicated that there were significant differences in PFS and OS between the two groups (P<0.05). Additionally, RPA grading of each factor in the combination group was a risk factor closely related with survival, with medium PFS in EGFR and KRAS mutation patients being 8.2 months and 11.2 months, and OS being 3.6 months and 6.3 months, respectively. Conclusions: Whole brain radiotherapy concomitant with target therapy is favorable for adverse reaction tolerance and clinical effects, being superior in treating brain metastasis in NSCLC patients with chemotherapy failure and thus deserves to be widely applied in the clinic.
引用
收藏
页码:5699 / 5703
页数:5
相关论文
共 19 条
  • [1] [Anonymous], J CLIN ONCOL
  • [2] Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial
    Brown, Paul D.
    Pugh, Stephanie
    Laack, Nadia N.
    Wefel, Jeffrey S.
    Khuntia, Deepak
    Meyers, Christina
    Choucair, Ali
    Fox, Sherry
    Suh, John H.
    Roberge, David
    Kavadi, Vivek
    Bentzen, Soren M.
    Mehta, Minesh P.
    Bruner, Deborah Watkins
    [J]. NEURO-ONCOLOGY, 2013, 15 (10) : 1429 - 1437
  • [3] Should Erlotinib Be Coadministered With Whole-Brain Radiotherapy in Patients With Brain Metastases and Non-Small-Cell Lung Cancer?
    Chamberlain, Marc C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (25) : 3164 - 3165
  • [4] Combination treatment with ionising radiation and gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor (EGFR) inhibitor, significantly inhibits bladder cancer cell growth in vitro and in vivo
    Colquhoun, A. J.
    Mchugh, L. A.
    Tulchinsky, E.
    Kriajevska, M.
    Mellon, J. K.
    [J]. JOURNAL OF RADIATION RESEARCH, 2007, 48 (05) : 351 - 360
  • [5] Dziggel L, 2013, STRAHLENTHER ONKOL
  • [6] Gianfranco A, 2012, EUR J CANCER, V48, P377
  • [7] Harth S, 2013, RADIOTHER ONCOL
  • [8] Temozolomide added to whole brain radiotherapy in patients with multiple brain metastases of non-small-cell lung cancer: a multicentric Austrian phase II study
    Hassler, Marco Ronald
    Pfeifer, Wolfgang
    Knocke-Abulesz, Thomas Hendrik
    Geissler, Klaus
    Altorjai, Gabriele
    Dieckmann, Karin
    Marosi, Christine
    [J]. WIENER KLINISCHE WOCHENSCHRIFT, 2013, 125 (15-16) : 481 - 486
  • [9] Concurrent whole brain radiotherapy and bortezomib for brain metastasis
    Lao, Christopher D.
    Friedman, Judah
    Tsien, Christina I.
    Normolle, Daniel P.
    Chapman, Christopher
    Cao, Yue
    Lee, Oliver
    Schipper, Matt
    Van Poznak, Catherine
    Hamstra, Daniel
    Lawrence, Theodore
    Hayman, James
    Redman, Bruce G.
    [J]. RADIATION ONCOLOGY, 2013, 8
  • [10] Clinical Application of Serum Tumor Associated Material (TAM) from Non-small Cell Lung Cancer Patients
    Li, Cheng-Guang
    Huang, Xin-En
    Xu, Lin
    Li, Ying
    Lu, Yan-Yan
    [J]. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (01) : 301 - 304